Back to Authors

Schreiner, Teri

0000-0002-3816-812X

A5055520593 | I51713134

Mayo Clinic

University of Colorado Anschutz

Citations 50

Epigenetic Age is Minimally Correlated with Leukocyte Telomere Length in Pediatric Onset Multiple Sclerosis (P6-1.005)

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210880

Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis

Neurology | February 3, 2025 | Volume: 104 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000210213 | PMID 39899789

Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States

Neurology | November 12, 2024 | Volume: 103 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000209991 | PMID 39531607

Patient and family views on research priorities and design of clinical trials and research studies in pediatric multiple sclerosis

Multiple Sclerosis Journal | September 17, 2024 | Volume: 30 | Issue: 11-12 | Pages: 1525-1543

10.1177/13524585241274580 | PMID 39286941

Background and Objectives: This survey study aimed to (1) identify patient/family research priorities in pediatric-onset multiple sclerosis (POMS), and (2) delineate optimized methods for research study/clinical trials design, engagement, and implementation. Methods: Participants were as follows: (1) parents of a child (<18 years) with POMS enrolled in a national registry, (2) adolescents (13–17 years) with POMS in the registry, and (3) adults (18–40 years) with POMS receiving care at a registry affiliated clinic. Of 293 eligible participants, 192 completed surveys. Results: Experiences with health care and medications were generally positive but there remain areas of priority improvement. Incentives to participate in clinical trials included medications previously tested and in pill form, bloodwork/study visits required ⩾ every 3 months, cognitive testing ⩽1 hour, compensation for travel and time, ability to continue current multiple sclerosis (MS) medication, option to take study medication if on placebo, and individualized study feedback. Priorities for clinical research were (1) psychosocial impact, (2) cognitive/academic impact, (3) environmental risk, and (4) nutrition. Conclusions: Results highlighted the importance of a holistic approach to study design and a focus on the impact of disease on daily life to best engage patients and families in POMS clinical trials and research.
Predictors of a Relapsing Course in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (S7.008)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000208303

Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (P11-6.005)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206450

Pediatric to Adult MS Transition Practices in the US (P1-6.007)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206205

Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US (S51.004)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s51.004

Distribution and predictors of disease severity in pediatric multiple sclerosisInvestigate the distribution of disease severity in pediatric-onset multiple sclerosis (MS). (S49.008)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s49.008

The Causal Effect of Serum Vitamin D Levels on Pediatric Multiple Sclerosis: A Mendelian Randomization Study (S29.007)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s29.007